Brand Reference: Pristiq
| Metric | Verified Benchmark | Source |
|---|---|---|
| Desvenlafaxine Succinate ER RxNorm Concept ID | 734064 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.3400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $142.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $11.40 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $15.00 / mo | 22 Zero-PHI Verified Patient Logs |
Delivers pure active O-desmethylvenlafaxine directly without requiring hepatic CYP2D6 conversion, eliminating pharmacogenomic ultra-rapid/poor-metabolizer plasma swings while providing steady SERT and NET dual blockade at a single 50 mg ceiling.
For self-pay patients filling Desvenlafaxine Succinate ER (NDC 00378-5405-93), direct wholesale and telehealth fulfillment drops monthly spend from $142.00 retail to $11.40 (92% savings against a $0.3400 CMS pharmacy acquisition baseline).
Clinical clearance of Desvenlafaxine Succinate ER (CYP2D6-Independent Active Metabolite SNRI) relies on direct ugt glucuronidation and 45% unchanged renal excretion (minimal cyp3a4) with a 11 hours half-life; patients absorbing at 80% oral bioavailability typically observe target onset around 2–4 weeks affective stabilization.
FDA clinical labeling for Desvenlafaxine Succinate ER restricts administration in maoi within 14 days; hypersensitivity to venlafaxine across 25 mg ER PO daily (taper/renal), 50 mg ER PO once daily (no added efficacy above 50 mg), with self-reported patient tracking dominated by sweating (17% of reports), ghost tablet shell in stool (normal) (14% of reports), nausea (13% of reports).
Across 22 verified cash-pay logs, Desvenlafaxine Succinate ER achieves a 84.30% Worth-It rating with out-of-pocket spend averaging $15.00/mo versus $142.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 25 mg ER PO daily (taper/renal) for Desvenlafaxine Succinate ER; monthly out-of-pocket dropped to $10.03 compared with $142.00 retail.
Completed 10 weeks on Desvenlafaxine Succinate ER (50 mg ER PO once daily (no added efficacy above 50 mg)). Zero notable side effects on steady dosing.
Consistent biomarker response on 25 mg ER PO daily (taper/renal) Desvenlafaxine Succinate ER sourced via Compounding ($13.22/mo cash pay without insurance prior authorization).